Buy RMD by Oct 30, 2026.

When I started researching ResMed (RMD), I thought I was analysing a medical device company. The debate seemed simple: Philips lost share after the recall, Fisher & Paykel is a capable competitor, and GLP 1 drugs may reduce future sleep apnea demand. After working through more than twenty questions design to analyse RMD’s competitive advantage, I reached a very different conclusion. The CPAP device is probably one of the weakest parts of ResMed's moat. ResMed generates roughly 87.5% of revenue …